Evidence map›Paper›PMID 26743316›Full record

ArticleScientific reports2016

Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.

Yuanyuan Li, Darren B Leneghan, Kazutoyo Miura, Daria Nikolaeva, Iona J Brian, Matthew D J Dicks, Alex J Fyfe, Sarah E Zakutansky, Simone de Cassan, Carole A Long and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Seroprevalence of antibodies toFrontiers in immunology · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuanyuan LiJenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Darren B LeneghanJenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Kazutoyo MiuraLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious. Disease/National Institutes of Health, Rockville, Maryland, USA.
Daria NikolaevaJenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Iona J BrianJenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Matthew D J DicksJenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Alex J FyfeJenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Sarah E ZakutanskyJenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Simone de CassanJenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Carole A LongLaboratory of Malaria and Vector Research, National Institute of Allergy and Infectious. Disease/National Institutes of Health, Rockville, Maryland, USA.
Simon J DraperJenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Adrian V S HillJenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.
Fergal HillIMAXIO, 69007 Lyon, France.
Sumi BiswasJenner Institute, University of Oxford, Oxford, OX3 7DQ, UK.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
Host Immune Responses to Antigens of Malaria ParasitesZIAAI001020 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LONG, CAROLE · 2009 to 2025
$13.6M
Medical Research Council G1000527NIGMS NIH HHS T32 GM007309
6 · The paper itself

Abstract

Transmission-blocking vaccines (TBV) target the sexual-stages of the malaria parasite in the mosquito midgut and are widely considered to be an essential tool for malaria elimination. High-titer functional antibodies are required against target antigens to achieve effective transmission-blocking activity. We have fused Pfs25, the leading malaria TBV candidate antigen to IMX313, a molecular adjuvant and expressed it both in ChAd63 and MVA viral vectors and as a secreted protein-nanoparticle. Pfs25-IMX313 expressed from viral vectors or as a protein-nanoparticle is significantly more immunogenic and gives significantly better transmission-reducing activity than monomeric Pfs25. In addition, we demonstrate that the Pfs25-IMX313 protein-nanoparticle leads to a qualitatively improved antibody response in comparison to soluble Pfs25, as well as to significantly higher germinal centre (GC) responses. These results demonstrate that antigen multimerization using IMX313 is a very promising strategy to enhance antibody responses against Pfs25, and that Pfs25-IMX313 is a highly promising TBV candidate vaccine.

Indexed as

Immunogenicity, VaccineAdenoviridaeAdjuvants, ImmunologicAnimalsAntibodies, ProtozoanAntigens, ProtozoanCulicidaeGene ExpressionGenetic VectorsGerminal CenterHumansInsect VectorsLife Cycle StagesMalaria, FalciparumMalaria VaccinesMiceAdjuvants, ImmunologicAntibodies, ProtozoanAntigens, ProtozoanMalaria VaccinesPfs25 protein, Plasmodium falciparumProtozoan ProteinsRecombinant Fusion ProteinsVaccines, Synthetic

Identifiers

PMID26743316
PMCPMC4705524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.